Last reviewed · How we verify
Intravenous bumetanide TID — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Intravenous bumetanide TID (Intravenous bumetanide TID) — Vrije Universiteit Brussel.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Intravenous bumetanide TID TARGET | Intravenous bumetanide TID | Vrije Universiteit Brussel | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Intravenous bumetanide TID CI watch — RSS
- Intravenous bumetanide TID CI watch — Atom
- Intravenous bumetanide TID CI watch — JSON
- Intravenous bumetanide TID alone — RSS
Cite this brief
Drug Landscape (2026). Intravenous bumetanide TID — Competitive Intelligence Brief. https://druglandscape.com/ci/intravenous-bumetanide-tid. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab